Results 351 to 360 of about 3,106,146 (396)
Some of the next articles are maybe not open access.
New cyclic peptide proteasome inhibitors
Bioorganic & Medicinal Chemistry Letters, 2009Here we report the study of a new series of vinyl ester cyclopeptide analogues synthesized on the basis of our previous development of a class of cyclopeptides derived from our linear prototype inhibitors. In these compounds, the exocyclic pharmacophoric unit Leu-VE was linked to the gamma-carboxyl group of the glutamic acid residue at the C-terminal ...
BALDISSEROTTO, Anna +3 more
openaire +3 more sources
Proteasome inhibitors for cancer therapy
Bioorganic & Medicinal Chemistry, 2012Proteasome, a large multicatalytic proteinase complex that plays an important role in processing of proteins, has been shown to possess multiple catalytic activities. Among its various activities, the 'chymotrypsin-like' activity of proteasome has emerged as the focus of drug discovery efforts in cancer therapy. Herein we report chiral boronate derived
Mohamed, Iqbal +6 more
openaire +2 more sources
Proteasome inhibitor patents (2010 – present)
Expert Opinion on Therapeutic Patents, 2014Over the past 3 years, numerous patents and patent applications have been submitted and published involving compounds designed to inhibit the proteasome. Proteasome inhibition has been of great interest in cancer research since disruption of proteolysis leads to a significant buildup of cytotoxic proteins and activation of apoptotic pathways ...
Rainer, Metcalf +3 more
openaire +2 more sources
Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management
Current Oncology Reports, 2020Perry Wu, O. Oren, M. Gertz, E. Yang
semanticscholar +1 more source
Oncology (Williston Park, N.Y.), 2008
Dharminder Chauhan, Kenneth C. Anderson
openaire +3 more sources
Dharminder Chauhan, Kenneth C. Anderson
openaire +3 more sources
Proteasome inhibitors in lung cancer
Critical Reviews in Oncology/Hematology, 2006Proteasome inhibition is a novel therapeutic approach that is being investigated in non-small cell and small cell lung cancer (NSCLC and SCLC). Proteasome inhibition affects a range of intracellular signals and disrupts the levels of numerous proteins, causing apoptosis via multiple pathways.
openaire +3 more sources
La Revue de medecine interne, 2005
Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis.Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use.
openaire +1 more source
Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis.Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use.
openaire +1 more source
2012
Proteasome inhibition is a rational approach to the therapy of multiple myeloma both alone and in combination with other agents, where proteasome inhibitors help induce chemosensitization and overcome drug resistance. These concepts were initially validated with laboratory-grade proteasome inhibitors and then with the clinically relevant peptide ...
openaire +1 more source
Proteasome inhibition is a rational approach to the therapy of multiple myeloma both alone and in combination with other agents, where proteasome inhibitors help induce chemosensitization and overcome drug resistance. These concepts were initially validated with laboratory-grade proteasome inhibitors and then with the clinically relevant peptide ...
openaire +1 more source
2004
The involvement of the 20S proteasome in the degradation of critical intracellular regulatory proteins has suggested the potential use of proteasome inhibitors as novel therapeutic agents being applicable in many different disease indications. Early synthetic inhibitors of the 20S proeteasome were relatively nonspecific compounds but proved to be ...
openaire +1 more source
The involvement of the 20S proteasome in the degradation of critical intracellular regulatory proteins has suggested the potential use of proteasome inhibitors as novel therapeutic agents being applicable in many different disease indications. Early synthetic inhibitors of the 20S proeteasome were relatively nonspecific compounds but proved to be ...
openaire +1 more source